A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas.
about
Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcomaCurrent Chemotherapy and Potential New Targets in Uterine LeiomyosarcomaPractice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus StatementManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinA Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Isolated cutaneous metastasis of uterine leiomyosarcoma: case report and review of literature.Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling.Major clinical research advances in gynecologic cancer in 2010Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.Dose-intensive chemotherapy in advanced adult soft tissue sarcoma.Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guidelineDistinctive outcome in patients with non-uterine and uterine leiomyosarcoma.Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue SarcomasThe role of adjuvant therapy in uterine leiomyosarcomaTreatment of advanced uterine leiomyosarcoma with aromatase inhibitorsProgress in gynecologic cancer research: the Gynecologic Oncology Group experienceA small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.A review of treatment of uterine leiomyosarcomas.High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches.Pharmacological treatment for uterine leiomyosarcomas.The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma.Chemotherapy for soft tissue sarcoma.Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis.Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992.Uterine sarcoma - current perspectives.Optimal management of uterine leiomyosarcoma.
P2860
Q24247966-CEDEAFC2-5C73-4CBB-ADCB-54EA9EADA6F8Q26767435-1AE002D7-957A-4A8C-8F32-EBE54FBF6F27Q28069514-FC06E859-51B9-477F-A542-1FDCDAE1735AQ28087771-AF7AAA90-BF13-48C5-A101-BE7ED79657F3Q30370631-C40E523B-F091-48A6-9FAF-23B86F618C23Q30439459-99FC4C17-A007-4403-85CD-A55705CF0E60Q33343936-1AF52AE1-B679-49B3-8454-1355D923C116Q33364318-115353CB-AD7F-49CD-A11D-99870382C688Q33379886-E4DE8258-9DFD-4530-88DC-00DB76262E64Q33397997-6E0A4D81-2C74-45FB-9FF6-A9AE71827FA5Q33415973-69D9F113-3D9C-4B0E-8CB4-67296A0B3A8DQ33438485-1F5F74F5-976B-469F-8616-6F6C1873835FQ34343122-21ED4F82-D153-4556-A50E-998811D18F2FQ34387629-6B0EA429-BEB6-483B-8F95-A03C65E2F4D3Q34517694-6954CC57-41C2-4E44-9AFF-ADF3A23B9010Q34621991-A0EF8658-B1D0-4A0A-990A-D5EC36BD0541Q34647409-D07E9212-F732-4A58-9828-64749362BBC3Q34647970-0DA2144E-EE6E-4D6F-98CB-EB8DA1CE6472Q34734533-8D6544E5-4D77-4F90-9E10-99A8AE05F6E3Q35025163-D82522F4-4502-44BD-AF99-00DD3F5C03CAQ35060432-C833D595-C139-4A54-84D8-CDF54AFF77FDQ35262870-8D48E22B-0512-472B-8CE0-A359C6357988Q35849504-232A1C7F-26DD-4796-95CB-C8F420BD4548Q36117059-89656013-8715-425E-B724-4C318A9BE67DQ36674041-AF28E316-622B-4CFB-96DE-12BC7C912822Q36674450-1E3F7217-1FDD-4F6F-A086-541B629CEA68Q36811788-8BE9DAF1-9FDB-4633-B28F-83FC1BD06FDFQ36855589-189DE85E-E53E-4071-846D-B46C5B566225Q36979840-26088954-D002-45C4-A2B7-03C04A0BA5D6Q37296303-6C466B1F-49C5-4B41-9EFE-C49DC70E84ECQ37634983-6BB0D9D4-DA05-4885-B311-235D7C808775Q38153648-D72DD908-17EF-496E-8109-9B7C085878F7Q38239833-5CA73BB7-800F-461F-9745-4EC691456DB3Q38270671-61095C6E-FFAE-417B-A4A2-4B9C0125D307Q38315670-F2D0FF7B-B247-4186-A229-61658D5C9C86Q38902113-27AA7477-FEF8-4316-94DB-60A1C56352D4Q39393499-C0F19F15-44BB-46E0-B593-B46B618AB44AQ40801101-7FDA45F6-AD9B-4DE6-8062-9B0C910688C0Q41634399-515C42F1-FA24-43C6-8DFA-41A9E5AC4665Q43173702-7A2CEED6-90A9-4402-9AD7-A5786A49C057
P2860
A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
A randomized study of adriamyc ...... in advanced uterine sarcomas.
@en
A randomized study of adriamyc ...... in advanced uterine sarcomas.
@nl
type
label
A randomized study of adriamyc ...... in advanced uterine sarcomas.
@en
A randomized study of adriamyc ...... in advanced uterine sarcomas.
@nl
prefLabel
A randomized study of adriamyc ...... in advanced uterine sarcomas.
@en
A randomized study of adriamyc ...... in advanced uterine sarcomas.
@nl
P2093
P1433
P1476
A randomized study of adriamyc ...... in advanced uterine sarcomas.
@en
P2093
Blessing JA
Creasman WT
Sedlacek TV
Thigpen JT
P304
P356
10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E
P407
P577
1983-08-01T00:00:00Z